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Centre for Tropical Diseases, Sacro Cuore Hospital, Negrar, Verona, ItalyAbstractStrongyloides stercoralis differs from the other soil-transmitted helminths because it puts infected subjects at risk of a fatal syndrome (in cases of
immunosuppression for medical conditions, immunosuppressant therapies, or both). Chronic strongyloidiasis is often a non-severe condition,
or is sometimes even asymptomatic, but diagnosis and effective therapy are essential in order to eradicate the infection and the life-long risk
involved. Therefore, diagnostic methods need to be highly sensitive. Stool microscopy and the Kato–Katz technique are commonly used in
prevalence studies, but they are inadequate for S. stercoralis detection. This is probably the main reason why the global prevalence has long
been underestimated. Concentration methods, the Baermann technique and Koga agar plate culture have better, but still unsatisfactory,
sensitivity. Serological tests have demonstrated higher sensitivity; although some authors have concerns about their speciﬁcity, it is
possible to deﬁne cut-off values over which infection is almost certain. In particular, the luciferase immunoprecipitation system technique
combined with a recombinant antigen (NIE) demonstrated a speciﬁcity of almost 100%. ELISA coproantigen detection has also shown
promising results, but still needs full evaluation. Molecular diagnostic methods are currently available in a few referral centres as in-house
techniques. In this review, on the basis of the performance of the different diagnostic methods, we outline diagnostic strategies that could
be proposed for different purposes, such as: prevalence studies in endemic areas; individual diagnosis and screening; and monitoring of
cure in clinical care and clinical trials.
Clinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and
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E-mail: zeno.bisofﬁ@sacrocuore.itIntroductionStrongyloides stercoralis is a soil-transmitted helminth (STH) that
is endemic in many areas of the world. Recently, it has been
estimated that at least 370 million people are infected [1]. In
some areas, 60% of the local population are infected [2,3].
This nematode has some peculiarities that differentiate it from
the other STHs. Humans acquire the infection by penetration of
infective larvae from contaminated soil through intact human
skin. The following phases of the life cycle (Fig. 1) are similar to
those of other nematodes such as hookworms (which is ac-
quired similarly) or Ascaris lumbricoides (which, in contrast, isClinical Microbiology and Infection © 2015 The Authors. Published by El
This is an open access artiacquired by ingestion, like most human parasites). Strongyloides,
however, has a unique characteristic that explains most of the
peculiar aspects of this parasite, which is that the infection can
be life-long because of the ‘autoinfective cycle’ [4]: the eggs
produced by the adult female hatch when they are still in the
intestinal lumen, and newborn larvae can penetrate the last part
of the bowel or the perianal skin, restarting the cycle inside the
human body (Fig. 1). For this reason, this infection tends to be
life-long, whereas infections with other STHs (namely: hook-
worm, A. lumbricoides, and Trichuris trichiura) are limited by the
lifespan of the adult worm, unless a new infection occurs.
Moreover, S. stercoralis infection can be fatal in a few days or
weeks in immunosuppressed patients [4–6]: the larvae rapidly
increase in number, and can disseminate throughout the human
body, often causing bacteraemia by intestinal translocation [7].
Treatment is often ineffective at this stage, and it is therefore
essential to diagnose and treat the infection at an earlier stage,
in order to remove a ‘time bomb’ [8]. Consequently, a furtherClin Microbiol Infect 2015; 21: 543–552
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FIG. 1. Life cycle of Strongyloides
stercoralis. 1, Filariform larvae
(450 nm) penetrate human skin. 2,
Larvae migrate to the lungs, trachea,
and pharynx, and are swallowed. 3,
Parthenogenetic adult females
(2 mm) penetrate the small-bowel
mucosa and release eggs. 4, Rabdi-
form larvae (250 nm) mature into
autoinfective ﬁlariform larvae, and
enter the circulation. 5, Rabdiform
larvae are shed in stools. 6, Free-
living 1-mm male and female adults
develop in the soil. 7, Sexual repro-
duction in the soil (indirect devel-
opment). 8, Filariform larvae develop
in the soil— infective for humans
(direct development).
544 Clinical Microbiology and Infection, Volume 21 Number 6, June 2015 CMIdifference from the other STHs is that, in this case, a simple
decrease in the parasite load is not an acceptable goal. Only the
complete eradication of the infection eliminates the future risk
of a fatal complication [9,10]. This is why diagnostic methods
for monitoring cure should be sensitive enough to detect even a
very light, residual infection after a partially effective treatment.
The same is true for the tests to be used in clinical trials, as
otherwise a persisting infection at a low level after treatment
may escape detection and therefore cause an overestimation of
a drug’s efﬁcacy [11].
Unfortunately, the commonly used faecal-based methods
have particularly low sensitivity. Examination of several stool
samples, as well as concentration techniques, improve the
performance of microscopy [12], which nevertheless remains
insufﬁciently sensitive. The Baermann method and Koga agar
plate culture (APC) are preferable, although they are cumber-
some and not routinely used [13].Clinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf of
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/liceAlternative methods, from serology to molecular biology, have
been developed and evaluated during the past few years [14].
The aim of this review is to outline what should be, based on
the state of the art from the most recent studies, the optimal
approach to the diagnosis of S. stercoralis infection for three
main purposes: (a) prevalence studies in endemic areas, (b)
individual diagnosis and screening, and (c) monitoring of cure in
clinical care and in clinical trials.
We will not provide a lengthy, technical description of each
diagnostic test and its accuracy: recent, excellent reviews on
these are available in the references.Prevalence studiesUntil now, faecal surveys on the prevalence of STHs have often
relied on stool concentration methods such as the Kato–KatzEuropean Society of Clinical Microbiology and Infectious Diseases, CMI, 21, 543–552
nses/by-nc-nd/4.0/)
CMI Buonfrate et al. The diagnosis of Strongyloides stercoralis 545[15–18], Mini-FLOTAC and McMaster [19] techniques. With
standard methods, prevalence studies are affected by a lack of
sensitivity. The larval output of S. stercoralis in stools is much
lower than that of the eggs of hookworms, T. trichiura, or
A. lumbricoides [20]. Moreover, if the peculiar autoinfective life
cycle (Fig. 1) prevails, the larval load in stools may be unde-
tectable [13,21,22]. Faecal surveys on STHs not aiming at
S. stercoralis with speciﬁc techniques miss most infections, and, as
a consequence, the global and local burdens of strongyloidiasis
are grossly underestimated [1,2,9,23]. Prevalence ﬁgures would
probably be different (but still far from reality) if multiple sam-
pling were to be used [12], but this is logistically difﬁcult to
implement in epidemiological studies. Better diagnostic tools are
needed for more correct estimation of S. stercoralis prevalence,
and also in order to assess whether (and where) speciﬁc control
measures are necessary [1,24]. Traditional methods that are
speciﬁc for S. stercoralis, such as the Baermann technique or
APC, provide more reliable prevalence ﬁgures [2], but are
cumbersome and rarely used in epidemiological surveys [13].
Novel diagnostic approaches to prevalence studies are not
necessarily based on ‘new’ technologies. An interesting
improvement in the sensitivity of stool microscopy for
S. stercoralis has been obtained with a very simple concentration
method, i.e. spontaneous tube sedimentation (STS) [23]. This is
a simple, innovative approach that does not require any so-
phisticated equipment, not even a centrifuge. Brieﬂy, 2–5 g of
stools is homogenized in 10 mL of saline solution and ﬁltered
through a surgical gauze into a 50-mL plastic tube, which is then
ﬁlled with more saline solution, plugged, and shaken vigorously.
The tube is left to stand for 45 min, after which the super-
natant is removed, and a sample is taken from the bottom and
put on a slide for microscopy. In a report from the Peruvian
Amazon, the prevalence of S. stercoralis according to this
method was 16%, whereas it was 22% with APC, and 0% with
the standard Kato–Katz technique [24]. For the other STHs,
the new method found the same prevalence as the Kato–KatzTABLE 1. Accuracy of conventional, faecal-based methods for St
studies
Reference Test(s) assessed Sensitivity (%) Speciﬁcity (%) Study cha
[31] Baermann 47 78.4 Accuracy a
Baermann 83.6 100 Accuracy a
assumed
Baermann 28.3 75.2 Accuracy a
[45] Direct
examination
21 100 Meta-analy
deﬁnitio
FECT 48 100
APC 89 100
Baermann 72 100
[26] C-FECT 48.1 100 Reference
100% by
the text
M-FECT 95.2 100
APC 94.2 100
APC, agar plate culture; C-FECT, conventional formol–ether concentration; FECT, formol–
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This is an open access artitechnique. Should this approach be corroborated by further
studies, STS could become a good and inexpensive method to
improve the rate of S. stercoralis detection in epidemiological
surveys. However, in another study, in Brazil, the sensitivity of
STS was lower than those of the Baermann technique and APC:
27.5% vs. 72.5% and 95%, respectively [25]. Another, simple
modiﬁcation of a classic method, formol–ether concentration
(FECT), which is not itself ideal method for S. stercoralis
detection, has been reported to have a sensitivity for
S. stercoralis that is similar to those of the Baermann technique
and APC [26]. The modiﬁcation consisted of using wire meshes
instead of gauze, and reducing the duration of exposure to
formalin. The accuracy of traditional, faecal-based methods,
according to recent papers, including a meta-analysis of studies
conducted between 1980 and 2013, is summarized in Table 1.
Molecular diagnosis was introduced later in parasitology than
in other ﬁelds of microbiology [27,28]. Its potential use for
prevalence surveys in resource-constrained countries is still
limited by cost and by the still low spread of its use outside
research laboratories. However, a few prevalence surveys have
been carried out with PCR. In a recent study in Kenya on hu-
man immunodeﬁciency virus-infected subjects, RT-PCR (sensi-
tivity, 83.3%) was able to detect more S. stercoralis infections
than the combination of wet preparation, the Kato–Katz
technique, and FECT (sensitivity, 16.7%) [29]: also, none of the
latter methods is adequate for S. stercoralis larva detection. In
Bangladesh and in Tanzania, a lower sensitivity of PCR methods
than of reference faecal methods was reported for the detec-
tion of low-intensity infections [30,31]. In detail, the study
conducted on samples from Bangladesh showed a PCR sensi-
tivity of 100% when it was assessed on samples with moderate-
intensity and high-intensity infection, and a sensitivity of 16%
when it was assessed on samples with low-intensity infection.
The second study, conducted on samples from Tanzania,
showed a PCR sensitivity of 17.4% as compared with the
Baermann technique.rongyloides stercoralis diagnosis according to recent, selected
racteristics
ssessed with PCR results as the reference standard
ssessed with a composite reference standard (PCR plus Baermann). Speciﬁcity
to be 100% for both methods
ssessed with a Bayesian approach to cope with the lack of a reference standard
sis of papers published between 1908 and 2013. Speciﬁcity considered to be 100% by
n. Reference standard based exclusively on the results of conventional methods
standard based on a combination of the three methods. Speciﬁcity considered to be
deﬁnition. Study designed to assess the sensitivity of a modiﬁed FECT as explained in
ether concentration; M-FECT, Modiﬁed formol–ether concentration.
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consistently reported a higher prevalence than those based on
faecal diagnosis [3,32–34]. Serology was also used for a survey
in the elderly population of Italy, in which a surprisingly high
prevalence was found in subjects with eosinophilia [35].
Different serological assays were recently evaluated [36,37],
and most of them showed a sensitivity ranging from 84% to 95%
in chronically infected subjects (Table 2). Speciﬁcity was also
good, and reached 100% above a given cut-off, at which
sensitivity remained acceptable [36]. Therefore, the use of
serology in community surveys is likely to provide a reliable
estimate of the true prevalence. Recently, a serological test
(NIE-ELISA) has been used on dried blood spots collected
through ﬁnger prick on ﬁlter paper, and the results were
comparable to those obtained with blood collected via veni-
puncture [38]. Standardization of this method (which has
already been used for decades for antibody testing of several
pathogens) for S. stercoralis infection would simplify the use of
serology for epidemiological surveys in endemic countries.
Among the ‘new’ methods, a particularly useful tool for
epidemiological surveys would be the antigen detection test in
stools, which has the potential to be developed as a rapid
immunochromatographic dipstick test [39]. However, further
research on the accuracy of this technique is needed [13,14].
Molecular methods can also be applied to large-scale
epidemiological and clinical investigation of intestinal parasites,
as reported in a recent review [27]. Real-time PCR provides aTABLE 2. Accuracy of serological methods for Strongyloides stercora
Reference (year) Test(s) assessed Sensitivity (%) Speciﬁcity (%) Study
[36] (2014) Bordier ELISAa 90.8 94.1 Study
pos
lack
IVD-ELISAb 92.3 97.4
NIE-ELISAc 70.8 91.1
IFATd 94.6 87.4
NIE-LIPSc 83.8 99.6
[37] (2014) SciMedx ELISAe 85.5 82.6 Study
forInBios-Strongy ELISAf 83.6 91.3
NIE-LIPSc 89.1 89.1
[41] (2007) AMC-ELISAd 93.3 95.0 Study
stro
Faec
Dipstickd 91.1 97.7
Bordier ELISAa 83.3 97.2
IVD-ELISAb 88.9 97.2
[42] (2010) IVD-ELISAb 91.2 93.3 As abo
[44] (2010) Crude Ag-ELISAd 97.0 100 Speciﬁ
RO
from
NIE-ELISAc 84.0 100
NIE-LIPSc 97.8 100
[43] (2008) NIE-ELISAc 97 95 Prospe
conNIE-LIPSc 97 100
[47] (2007) IFATd 74.1 98.4 Accur
refe
[49] (2006) IFATd 97.4 97.9 Refere
Refe
neg
[55] (2011) IFATd 73 NA Study
Ag, antigen; HIV, human immunodeﬁciency virus; IFAT, immunoﬂuorescence antibody test; LI
characteristic.
aCrude Ag (S. ratti), commercially available.
bCrude Ag (S. stercoralis), commercially available.
cRecombinant Ag, in-house.
dCrude Ag (S. stercoralis), in-house.
eCommercially available for study purpose only.
fRecombinant Ag, commercially available.
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automation, and provides the possibility of an integrated high-
throughput approach for the detection of a wide range of
parasites, bacteria, and viruses.Individual diagnosis and screeningClinical clues indicating S. stercoralis infection are poor and non-
speciﬁc [14]. What matters more on an individual basis is to
optimize the negative predictive value of the diagnostic
approach; therefore, highly sensitive tests are needed. A
particular case is that of individuals who are candidates for
immunosuppressive treatment. In particular, screening for
S. stercoralis with appropriate techniques should be included in
all transplant screening protocols, both for potentially exposed
recipients and for donors [40].
Serological methods are the most sensitive available diag-
nostic tools [13,14]. A variety of antigens have been used to
develop serological tests. Two commercially available tests
(Bordier ELISA and IVD-ELISA) use Strongyloides ratti and
S. stercoralis larvae, respectively [41,42]. In recent years, a re-
combinant antigen named NIE (ﬁrst identiﬁed in 2002) has been
used to develop an ELISA test (NIE-ELISA) and a luciferase
immunoprecipitation system (NIE-LIPS) [43,44]. A new
commercially available, NIE-based ELISA test was recently
compared with another ELISA test (SciMedx Strongyloideslis diagnosis according to selected studies published after 2005
characteristics
using a composite reference standard of faecal and serological tests (denominator for
itives: samples with positive stool or 3/5 positive serological tests) to cope with the
of a reference standard. Limits: retrospective study design
mainly aimed at assessing percentage agreement of the three tests. Reference standard
positives: samples with 2/3 positive serological tests— faecal results not considered
using a panel of serum specimens from a population composed of patients with proven
ngyloidiasis, healthy controls, and patients with various parasitic and other diseases.
al results used as a unique reference standard
ve
city predetermined at 100% for all methods by the use of cut-off values obtained from
C curves for 90 samples from patients with positive stools and ten healthy controls
a non-endemic area
ctive design. Speciﬁcity assessed in a small group of healthy controls, but also
ﬁrmed (for LIPS) in samples from patients with ﬁlarial and other helminth infections
acy (high titre) determined with latent class analysis to cope with the lack of a
rence standard. Coprological methods used for the model not optimal for S. stercoralis
nce standard for sensitivity: samples from patients with S. stercoralis larvae in stools.
rence standard for speciﬁcity: samples from controls with no risk of infection and
ative stools. Cross-reactivity assessed separately
on HIV-positive subjects, with average CD4 count of 373/μL
PS, luciferase immunoprecipitation system; NA, not available; ROC, receiver operating
European Society of Clinical Microbiology and Infectious Diseases, CMI, 21, 543–552
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and with NIE-LIPS [37]. The last of these, which has not yet
been made commercially available, was more accurate than the
two commercial tests. Recent, selected studies on the accuracy
of serological methods are summarized in Table 2; this dem-
onstrates, in general, not only high sensitivity, as expected, but
also speciﬁcity of >90% in most reports, although the results
should be interpreted with caution, as they are inﬂuenced by
the kind of reference standard used.
In fact, a methodological problem in assessing test accuracy is
that a gold standard is not available. Faecal results alone do not
provide an acceptable reference standard, owing to their poor
sensitivity. For this reason, diagnostic studies on traditional,
faecal-based methods (such as those reported in Table 1) tend
to overestimate the test sensitivity. A recent meta-analysis on
the evaluation of conventional parasitological methods found
the highest sensitivity (89%) for APC, followed by the Baer-
mann technique (72%), FECT (48%), and direct wet smear
(21%), but the results were hampered by the reference stan-
dard used, which was also based on faecal methods [45].
If the larval output in stool is minimal, which is often the case
in chronic infections, any faecal test would be likely to miss the
infection, whereas a serological test give a positive result. If the
accuracy of serology were to be evaluated against a faecal-based
reference standard, discordant results (in particular: faecal-
negative and serology-positive results) would be impossible to
classify. This problem has been circumvented in several ways.
Some researchers have estimated the accuracy of serology
(along with the prevalence of S. stercoralis infection in selected
areas) by using special statistical techniques, such as a Bayesian
model [46] or latent class analysis [47]. More recently, the
accuracy of ﬁve different serological tests was evaluated with a
composite reference standard [48]. The tests evaluated were
the two NIE-based assays and the two commercial ELISAs
mentioned above, plus an in-house immunoﬂuorescence anti-
body test (IFAT) [49], using for antigen preparation intact
S. stercoralis ﬁlariform larvae obtained from a charcoal faecal
culture [36]. The negative predictive value was almost 100% for
all tests at low prevalence. This means that a single test is
sufﬁcient to rule out the infection, if it gives a negative result.
This is not so for a recently acquired infection, e.g. in travellers,
for which the sensitivity of serology was found to be much
lower than for chronic infections in immigrants: 73% vs. 98%
[50]. Acute strongyloidiasis in travellers [51] is a rare occur-
rence [8], but, in cases of clinical suspicion, the clinician should
be reminded that the serology is not sufﬁcient to rule out the
infection if it gives a negative result. For patients with high
pretest probability (e.g. a subject with a generalized itching and
eosinophilia and a compatible exposure history, or the
screening of a transplant candidate from a high-prevalenceClinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf
This is an open access artiarea), a single, negative serological test result will not safely
exclude the infection, and a second serological test, preferably
based on a different antigen, and/or a faecal-based test, should
be added. The choice of the latter depends on local availability,
and clear evidence supporting the use of a molecular method
[52–54] rather than a ‘traditional’ one is still lacking. A potential
alternative to excess testing might be presumptive treatment, as
postulated by some [14], considering that the treatment agent
of choice, ivermectin, is generally well tolerated. The cost-
effectiveness of the two competing approaches has yet to be
evaluated [14]. We think that presumptive treatment is justiﬁed
if sensitive diagnostic tools are not available, or, even if they are
and the results are negative, when a potentially exposed patient
is symptomatic and other causes have been reasonably
excluded. A particular case is the diagnosis of S. stercoralis in a
subject who is already immunosuppressed, owing to medical
conditions or treatments. Immunosuppression may cause
diminished sensitivity of serum antibody detection [13,55];
therefore, serology should never be used alone in those sub-
jects. Moreover, in cases of hyperinfection due to immuno-
suppression, the larval output is much higher, resulting in much
better sensitivity of all faecal-based methods [13].
The use of molecular methods in parasitological diagnosis is
still limited to a few reference laboratories, mostly in indus-
trialized countries [52]. Only a few commercial kits are avail-
able, and the protocols used are not standardized. Major
differences concern DNA extraction, the size and mode of
preservation (if any) of the stool specimens, and the solutions
used to neutralize potential PCR inhibitors. All of these,
together with the critical issue of ampliﬁcation, affect sensitivity,
as mentioned above. Moreover, the criteria for the assessment
of test accuracy are also variable (Table 3). Although the
sensitivity is certainly lower than that of serology, it is also still
unclear whether PCR and/or RT-PCR at least equal the sensi-
tivity of the best faecal-based traditional methods, such as the
Baermann technique or APC, as results from different studies
are not in complete agreement [13,31,56,57]. On the other
hand, the costs of RT-PCR are not necessarily higher than those
of traditional microscopy [56], and may be even lower,
considering the time saved [27,56].Monitoring of cure in clinical care and clinical
trialsThe lack of a reference standard for diagnosis is a serious
problem when the efﬁcacy of a treatment is evaluated. A limited
number of clinical trials on S. stercoralis treatment have been
conducted during the last three decades, usually comparing
thiabendazole, albendazole, and ivermectin. Although noof European Society of Clinical Microbiology and Infectious Diseases, CMI, 21, 543–552
cle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
TABLE 3. Main characteristics of molecular biology techniques for Strongyloides stercoralis diagnosis according to recent studies
Reference
(year)
Test assessed/
region targeted Extraction/type of specimen Sensitivity Speciﬁcity (%) Study characteristics
[28] (2011) Fret-PCR/18S rRNA QIAamp DNA stool MiniKit/
100 mg unpreserved
LOD 4 × 102 copies/
reactions (40 larvae
per gram)
100 Sensitivity calculated as LOD
Speciﬁcity evaluated in a control group of negative
stool samples from healthy adults plus stool samples
positive for other parasites
[30] (2013) RT-PCR/18S rRNA Comparison of ﬁve methods:
four manual and one
automatic
10−2 dilution LOD 100 Sensitivity calculated as LOD in serial dilutions of
Strongyloides ratti larvae spiked into stools
Speciﬁcity calculated in 58 deﬁnitely negative samples
[52] (2009) RT-PCR/18S rRNA,
cytochrome c
oxidase, sequence
repeat
QIAamp DNA stool MiniKit/
100 mg unpreserved; 2%
PvPP
33/38a (87%)
or
33/54b (61%)
100 For sensitivity, the denominator was: positive
Baermann or singlea or duplicateb APC. RT-PCR also
detected 12 samples negative with both techniques
Speciﬁcity was calculated by checking the
oligonucleotide sequences on BLAST and in 145
deﬁnitely negative stool samples
[54] (2011) Single and nested PCR/
ITS1-5.8S-ITS-2
QIAamp DNA stool MiniKit/
3 g preserved sample (EtOH
70%)
Single PCR 100%
Nested PCR 75%
100 Sensitivity calculated in 16 APC-positive samples
Speciﬁcity calculated in stool-negative control group
(35 APC-negative samples)
[59] (2014) RT-PCR/18S rRNA QIAamp DNA stool MiniKit/
200 mg unpreserved
LOD 0.1 pg 100 Sensitivity calculated as LOD
Speciﬁcity calculated in 13 deﬁnitely negative samples
[73] (2014) LAMP/28S rRNA QIAamp DNA stool MiniKit/
100 mg unpreserved; 2%
PvPP
LOD <10 copies 100 Sensitivity calculated as LOD
Speciﬁcity calculated in 38 stool samples deﬁnitely
negative for S. stercoralis
[87] (2011) RT-PCR/18S rRNA QIAamp DNA stool MiniKit LOD 10 copies 100 Sensitivity calculated as LOD
Speciﬁcity tested against DNA controls derived from
a wide range of intestinal microorganisms
LAMP, loop-mediated isothermal ampliﬁcation; LOD, limit of detection; PvPP, Polyvinylpolypyrrolidone.
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the evidence consistently shows that albendazole is unsatisfac-
tory [58–60], and should no longer be considered as a treat-
ment for this condition, although, in many countries, it is the
only drug registered for this use. Thiabendazole and ivermectin
have similar efﬁcacies, but the much better tolerability of the
latter has made it the drug of choice worldwide [36]. So far, all
trials but one have been based exclusively on faecal methods.
Ivermectin has been found to be highly effective (>90% in most
trials), but the relative lack of sensitivity of faecal diagnosis is
likely to have caused an overestimation of the drug efﬁcacy
[14]. The only trial that included serology in the assessment of
cure [61] found much lower efﬁcacy of ivermectin than previ-
ously reported. Serology should be mandatory for inclusion in a
trial and as a marker of cure in combination with faecal
methods. If serology is positive at inclusion, failure of it to
become negative at 6–12 months of follow-up, or at least to
show a consistent decrease in serological titre, should be
regarded as a potential failure, even if faecal tests give negative
results [13]. Several studies have reported that the serological
titre usually tends to decrease after treatment [49,62,63]. For
example, in a study in Italy on an in-house IFAT, 60% of the
subjects showed either complete seroreversion or a decrease
in antibody titre of at least two-fold within 4 months of treat-
ment [49]. Another study in Australia on an in-house ELISA
based on crude antigen showed, for 65% of the patients, either
complete negativization or a consistent decrease in optical
density within an average of 9 months after treatment [64]. In
another and more recent study in Spain, using the commercially
available IVD-ELISA, the same result was obtained for 81% ofClinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf of
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licethe treated patients after a 6-month follow-up [63]. Unfortu-
nately, just as for diagnosis, a reference standard for cure is not
available. We have recently shown, using a surrogate, com-
posite reference standard for cure, that antibody titre (of IFAT,
IVD-ELISA, Bordier ELISA, NIE-ELISA, and NIE-LIPS) tends to
consistently decrease after effective treatment [11]. The difﬁ-
culty is that negativization, or at least a consistent reduction in
titre, takes much longer than with faecal-based tests, which
hampers the use of serology for clinical trials in endemic
countries, because of the risk of re-infection during the follow-
up period. A randomized controlled trial is currently ongoing in
Italy, Spain and the UK on single-dose ivermectin vs. multiple-
dose ivermectin, combining serology with faecal methods for
inclusion and for monitoring cure, with follow-up carried out 6
and 12 months after treatment (https://clinicaltrials.gov/ct2/
show/NCT01570504). This trial is only including immuno-
competent subjects who are not exposed to the risk of re-
infection (immigrants from endemic areas or European sub-
jects who were infected earlier in life when transmission was
still occurring in Italy and Spain). The criterion for cure is a
negative faecal test result at follow-up (comprising APC and/or
RT-PCR), plus at least a two-fold reduction in antibody titre.
An assessment of the main diagnostic tools for the three
main purposes is summarized in Table 4.Possible new scenariosSerology for S. stercoralis is likely to be further improved by the use
of recombinant antigens. Recently, with the same NIE antigenEuropean Society of Clinical Microbiology and Infectious Diseases, CMI, 21, 543–552
nses/by-nc-nd/4.0/)
TABLE 4. Summary of diagnostic approaches to Strongyloides stercoralis diagnosis in epidemiological surveys, individual diagnosis
and screening, inclusion in clinical trials, and monitoring of cure
Diagnostic tools Prevalence surveys
Individual diagnosis and
screening
Clinical trials and
assessment of cure References
STS Potential use for faecal surveys
instead of the Kato–Katz
technique
Suitable for basic laboratories in
endemic areas; conﬂicting results
on sensitivity
Unsuitable [23–25]
Formol–ether
concentration
With simple modiﬁcation, may
approach Baermann or APC, but
more studies are needed
Unsuitable (suboptimal sensitivity) Unsuitable [13,14]
Baermann, Koga APC More reliable ﬁgures than with other
faecal tests
Up to now the most accurate faecal
tests, but do not exclude infection
if negative; cumbersome, not
routinely performed
Suitable, but will tend to
overestimate cure rate if used
alone
[2,13]
PCR, RT-PCR Potentially excellent tools; ﬁgures
comparable with those obtained
with Baermann or APC according
to some studies
Good, potentially cost-effective,
allow simultaneous detection of
multiple pathogens; low sensitivity
for light infections according to
some studies
May become reference faecal
tests for inclusion in trials and
cure monitoring, but more
evidence is needed
[14,27,29–31,52,53,56,57,87]
Serology (IFAT,
commercial ELISAs,
NIE-LIPS)
Prevalence invariably higher than
with any faecal method; may
overestimate, because of false
positives and cross-reactivity, but,
with all tests, excellent PPV at
higher cut-offs. The use of dried
blood spots is a potential
innovation for surveys
Most sensitive test, should be
mandatory. NPV 100% at low
prevalence (can be used alone if
negative). Need for a second test
for high prevalence or suspicion.
Promising development with
recombinant antigens. NIE-LIPS
100% speciﬁc. All serological tests
lose sensitivity in
immunocompromised patients
(faecal test mandatory)
Should be mandatory. Use in
combination with a faecal
test. Cure determined by
negativitization of faecal test
plus negativization or
consistent reduction in titre
of serology
[3,11,13,14,32,33,35–37,43,44,61,63]
IFAT, immunoﬂuorescence antibody test; LIPS, luciferase immunoprecipitation system; NPV, negative predictive value; PPV, positive predictive value; STS, sedimentation in tube.
CMI Buonfrate et al. The diagnosis of Strongyloides stercoralis 549mentioned above, a new, rapid serological assay has been devel-
oped, making use of novel, high-sensitivity diffractive optics tech-
nology, providing, in <30 min, results that were fully consistent
with those ofNIE-ELISA [65]. Incorporation of other recombinant
proteins of S. stercoralis in the same platform in a multiplex format
might further increase the accuracy of this method.
In molecular biology research, another interesting area is
loop-mediated isothermal ampliﬁcation (LAMP). It is charac-
terized by the use of six different primers speciﬁcally designed
to recognize eight distinct regions on a target gene, with
ampliﬁcation only occurring if all primers bind and form a
product [66]. In the last few years, parasitologists have adapted
the LAMP approach for the detection of several parasites,
including Echinococcus [67–69], Taenia [70–72], Loa loa [73,74],
Opistorchis [75], Clonorchis [76], ﬁlariae [77], and Trichinella [78].
The method appears to be promising for S. stercoralis too [79],
although it still needs to be validated in clinical practice [13].
LAMP is cheaper than real-time PCR, has reasonably good
sensitivity and speciﬁcity, and could be used as a diagnostic tool
for ﬁeld testing [80].
The recent ﬁnding that microRNAs (miRNAs) can be
released from mammalian cells and tissues into the circulation
has stimulated extensive interest in the potential use of these
molecules as biomarkers [81–83]. miRNAs are small, non-
coding RNA molecules (containing ~22 nucleotides) that
function in RNA silencing and post-transcriptional regulation
of gene expression. miRNA-based diagnostics are being
developed for a number of diseases, and, although RT-PCR is
the most common detection method at present, there is greatClinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf
This is an open access artiinterest in improving and diversifying detection technologies,
which may provide more ﬁeld-friendly tools, as suggested by a
recent study reporting the experimental use of this approach
for Schistosoma infection [84]. The authors show that miRNAs
derived from Schistosoma mansoni are present in infected
mouse and human serum, and offer advantages over endoge-
nous miRNA as biomarkers of infection. To our knowledge,
there are not yet any published studies regarding the investi-
gation of S. stercoralis-derived miRNAs in host serum. It would
be of great interest to investigate whether this could represent
a novel, sensitive biomarker for the diagnosis of strongyloidi-
asis in humans.
A recent study focused on detecting genes essential for
parasitism in S. stercoralis, using microarray technologies and
next-generation sequencing [85]. According to the authors, a
comprehensive genome project, comprising not only
S. stercoralis but also S. ratti, Strongyloides papillosus, Strongyloides
venezuelensis, and Parastrongyloides trichosuri, is nearing
completion, and the annotated genomes of these parasites will
be published in the very near future. If a subset of genes
regulated preferentially in L3a could be identiﬁed, this might
contain potential targets for intervention to prevent the most
serious complications of human strongyloidiasis [85].ConclusionsIn low–middle-income countries, just as in developed nations,
there is a trend for there to be a decrease in the number ofof European Society of Clinical Microbiology and Infectious Diseases, CMI, 21, 543–552
cle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
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tion of parasites. Also, although not only, for this reason,
diagnostic methods that are not dependent on skilled micros-
copists are needed; therefore, the application of molecular as-
says is expected to increase in parasitology, which is still lagging
behind in this respect, as compared with virology or bacteri-
ology. With the relatively recent advent of microarray tech-
nology, and the advances in lab-on-chip systems, potentially
allowing the simultaneous and fully automated detection of
multiple pathogens [86], this will become even more true.
However, in the particular case of S. stercoralis infection, mo-
lecular diagnosis has yet to demonstrate an optimal sensitivity,
which is particularly required for this parasite, for which even
very light infections are relevant and must be detected and
treated. Until then, molecular diagnosis is unlikely to completely
replace the other diagnostic techniques, and serological assays,
having so far shown the highest sensitivity, will remain the
mainstay of S. stercoralis screening, as well as an essential tool
for prevalence surveys and for cure assessment in clinical set-
tings and in treatment trials.Transparency declarationThe authors declare that they have no conﬂicts of interest.References[1] Bisofﬁ Z, Buonfrate D, Montresor A, Requena-Mendez A, Munoz J,
Krolewiecki AJ, et al. Strongyloides stercoralis: a plea for action. PLoS
Negl Trop Dis 2013;7(5):e2214.
[2] Schar F, Trostdorf U, Giardina F, Khieu V, Muth S, Marti H, et al.
Strongyloides stercoralis: global distribution and risk factors. PLoS Negl
Trop Dis 2013;7(7):e2288.
[3] Buonfrate D, Mena MA, Angheben A, Requena-Mendez A, Munoz J,
Gobbi F, et al. Prevalence of strongyloidiasis in Latin America: a sys-
tematic review of the literature. Epidemiol Infect 2015 Feb;143(3):
452–60.
[4] Greaves D, Coggle S, Pollard C, Aliyu SH, Moore EM. Strongyloides
stercoralis infection. BMJ 2013;347:f4610.
[5] Buonfrate D, Requena-Mendez A, Angheben A, Munoz J, Gobbi F, Van
Den Ende J, et al. Severe strongyloidiasis: a systematic review of case
reports. BMC Infect Dis 2013;13:78.
[6] Lam CS, Tong MK, Chan KM, Siu YP. Disseminated strongyloidiasis: a
retrospective study of clinical course and outcome. Eur J Clin Micro-
biol Infect Dis 2006 Jan;25(1):14–8.
[7] Mejia R, Nutman TB. Screening, prevention, and treatment for
hyperinfection syndrome and disseminated infections caused by
Strongyloides stercoralis. Curr Opin Infect Dis 2012 Aug;25(4):458–63.
[8] Caumes E, Keystone JS. Acute strongyloidiasis: a rarity. Chronic
strongyloidiasis: a time bomb! J Travel Med 2011;18(2):71–2.
[9] Olsen A, van Lieshout L, Marti H, Polderman T, Polman K,
Steinmann P, et al. Strongyloidiasis—the most neglected of the
neglected tropical diseases? Trans R Soc Trop Med Hyg 2009
Oct;103(10):967–72.Clinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf of
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/lice[10] Krolewiecki AJ, Lammie P, Jacobson J, Gabrielli AF, Levecke B,
Socias E, et al. A public health response against Strongyloides stercoralis:
time to look at soil-transmitted helminthiasis in full. PLoS Negl Trop
Dis 2013;7(5):e2165.
[11] Buonfrate D, Sequi M, Mejia R, Cimino RO, Krolewiecki AJ,
Albonico M, et al. Accuracy of ﬁve serologic tests for the follow up of
Strongyloides stercoralis infection. PLoS Negl Trop Dis 2015 Feb;9(2):
e0003491.
[12] Knopp S, Mgeni AF, Khamis IS, Steinmann P, Stothard JR, Rollinson D,
et al. Diagnosis of soil-transmitted helminths in the era of preventive
chemotherapy: effect of multiple stool sampling and use of different
diagnostic techniques. PLoS Negl Trop Dis 2008:e331.
[13] Requena-Mendez A, Chiodini P, Bisofﬁ Z, Buonfrate D, Gotuzzo E,
Munoz J. The laboratory diagnosis and follow up of strongyloidiasis: a
systematic review. PLoS Negl Trop Dis 2013;7(1):e2002.
[14] Requena-Mendez A, Buonfrate Dora, Bisofﬁ Zeno, Gutiérrez JM.
Advances in the diagnosis of human strongyloidiasis. Curr Trop Med
Rep 2014;1(4):s40475.
[15] Cepon-Robins TJ, Liebert MA, Gildner TE, Urlacher SS, Colehour AM,
Snodgrass JJ, et al. Soil-transmitted helminth prevalence and infection
intensity among geographically and economically distinct Shuar com-
munities in the Ecuadorian Amazon. J Parasitol 2014 Oct;100(5):
598–607.
[16] Kaminsky RG, Ault SK, Castillo P, Serrano K, Troya G. High preva-
lence of soil-transmitted helminths in Southern Belize—highlighting
opportunity for control interventions. Asian Paciﬁc J Trop Biomed
2014 May;4(5):345–53.
[17] Joseph SA, Casapia M, Blouin B, Maheu-Giroux M, Rahme E,
Gyorkos TW. Risk factors associated with malnutrition in one-year-
old children living in the Peruvian Amazon. PLoS Negl Trop Dis 2014
Dec;8(12):e3369.
[18] Davis SM, Worrell CM, Wiegand RE, Odero KO, Suchdev PS, Ruth LJ,
et al. Soil-transmitted helminths in pre-school-aged and school-aged
children in an urban slum: a cross-sectional study of prevalence, dis-
tribution, and associated exposures. Am J Trop Med Hyg 2014
Nov;91(5):1002–10.
[19] Barda B, Cajal P, Villagran E, Cimino R, Juarez M, Krolewiecki A, et al.
Mini-Flotac, Kato–Katz and McMaster: three methods, one goal;
highlights from north Argentina. Parasit Vectors 2014;7:271.
[20] Glinz D, Silue KD, Knopp S, Lohourignon LK, Yao KP, Steinmann P,
et al. Comparing diagnostic accuracy of Kato–Katz, Koga agar plate,
ether-concentration, and Flotac for Schistosoma mansoni and soil-
transmitted helminths. PLoS Negl Trop Dis 2010;4(7):e754.
[21] Sato Y, Kobayashi J, Toma H, Shiroma Y. Efﬁcacy of stool examination
for detection of Strongyloides infection. Am J Trop Med Hyg 1995
Sep;53(3):248–50.
[22] Uparanukraw P, Phongsri S, Morakote N. Fluctuations of larval
excretion in Strongyloides stercoralis infection. Am J Trop Med Hyg 1999
Jun;60(6):967–73.
[23] Tello R, Terashima A, Marcos LA, Machicado J, Canales M,
Gotuzzo E. Highly effective and inexpensive parasitological tech-
nique for diagnosis of intestinal parasites in developing countries:
spontaneous sedimentation technique in tube. Int J Infect Dis 2012
Jun;16(6):e414–416.
[24] Machicado J, Marcos LA, Tello R, Canales M, Terashima A, Gotuzzo E.
Diagnosis of soil-transmitted helminthiasis in an Amazonic community
of Peru using multiple diagnostic techniques. Trans R Soc Trop Med
Hyg 2012 Jun;106(6):333–9.
[25] Ines Ede J, Souza JN, Santos RC, Souza ES, Santos FL, Silva ML, et al.
Efﬁcacy of parasitological methods for the diagnosis of Strongyloides
stercoralis and hookworm in faecal specimens. Acta Trop 2011;120(3):
206–10.
[26] Anamnart W, Intapan PM, Maleewong W. Modiﬁed formalin-ether
concentration technique for diagnosis of human strongyloidiasis.
Korean J Parasitol 2013 Dec;51(6):743–5.European Society of Clinical Microbiology and Infectious Diseases, CMI, 21, 543–552
nses/by-nc-nd/4.0/)
CMI Buonfrate et al. The diagnosis of Strongyloides stercoralis 551[27] Verweij JJ, Stensvold CR. Molecular testing for clinical diagnosis and
epidemiological investigations of intestinal parasitic infections. Clin
Microbiol Rev 2014 Apr;27(2):371–418.
[28] Janwan P, Intapan PM, Thanchomnang T, Lulitanond V, Anamnart W,
Maleewong W. Rapid detection of Opisthorchis viverrini and Strongyloides
stercoralis in human fecal samples using a duplex real-time PCR and
melting curve analysis. Parasitol Res 2011 Dec;109(6):1593–601.
[29] Arndt MB, John-Stewart G, Richardson BA, Singa B, van Lieshout L,
Verweij JJ, et al. Impact of helminth diagnostic test performance on
estimation of risk factors and outcomes in HIV-positive adults. PloS
One 2013;8(12):e81915.
[30] Sultana Y, Jeoffreys N, Watts MR, Gilbert GL, Lee R. Real-time poly-
merase chain reaction for detection of Strongyloides stercoralis in stool.
Am J Trop Med Hyg 2013 Jun;88(6):1048–51.
[31] Knopp S, Salim N, Schindler T, Karagiannis Voules DA, Rothen J,
Lweno O, et al. Diagnostic accuracy of Kato–Katz, Flotac, Baermann,
and PCR methods for the detection of light-intensity hookworm and
Strongyloides stercoralis infections in Tanzania. Am J Trop Med Hyg 2014
Mar;90(3):535–45.
[32] Yori PP, Kosek M, Gilman RH, Cordova J, Bern C, Chavez CB, et al.
Seroepidemiology of strongyloidiasis in the Peruvian Amazon. Am J
Trop Med Hyg 2006 Jan;74(1):97–102.
[33] Buonfrate D, Angheben A, Gobbi F, Munoz J, Requena-Mendez A,
Gotuzzo E, et al. Imported strongyloidiasis: Epidemiology, pre-
sentations, and treatment. Curr Infect Dis Rep 2012 Jun;14(3):256–62.
[34] Sultana Y, Gilbert GL, Ahmed BN, Lee R. Strongyloidiasis in a high risk
community of Dhaka, Bangladesh. Trans R Soc Trop Med Hyg 2012
Dec;106(12):756–62.
[35] Abrescia FF, Falda A, Caramaschi G, Scalzini A, Gobbi F, Angheben A,
et al. Reemergence of strongyloidiasis, northern Italy. Emerg Infect Dis
2009 Sep;15(9):1531–3.
[36] Bisofﬁ Z, Buonfrate D, Sequi M, Mejia R, Cimino RO, Krolewiecki AJ,
et al. Diagnostic accuracy of ﬁve serologic tests for Strongyloides ster-
coralis infection. PLoS Negl Trop Dis 2014;8(1):e2640.
[37] Anderson NW, Klein DM, Dornink SM, Jespersen DJ, Kubofcik J,
Nutman TB, et al. Comparison of three immunoassays for detection of
antibodies to Strongyloides stercoralis. Clin Vaccine Immunol 2014
May;21(5):732–6.
[38] Mounsey K, Kearns T, Rampton M, Llewellyn S, King M, Holt DC, et al.
Use of a dried blood spots to deﬁne antibody response to the
Strongyloides stercoralis recombinant antigen NIE. Acta Trop 2014;138:
78–82.
[39] Sykes AM, McCarthy JS. A coproantigen diagnostic test for Strong-
yloides infection. PLoS Negl Trop Dis 2011;5(2):e955.
[40] Le M, Ravin K, Hasan A, Clauss H, Muchant DG, Pasko JK, et al. Single
donor-derived strongyloidiasis in three solid organ transplant re-
cipients: case series and review of the literature. Am J Transplant 2014
May;14(5):1199–206.
[41] Van Doorn HR, Koelewijn R, Hofwegen H, Gilis H, Wetsteyn JC,
Wismans PJ, et al. Use of enzyme-linked immunosorbent assay and
dipstick assay for detection of Strongyloides stercoralis infection in
humans. J Clin Microbiol 2007;45(2):438–42.
[42] Bon B, Houze S, Talabani H, Magne D, Belkadi G, Develoux M, et al.
Evaluation of a rapid enzyme-linked immunosorbent assay for diagnosis
of strongyloidiasis. J Clin Microbiol 2010 May;48(5):1716–9.
[43] Ramanathan R, Burbelo PD, Groot S, Iadarola MJ, Neva FA,
Nutman TB. A luciferase immunoprecipitation systems assay enhances
the sensitivity and speciﬁcity of diagnosis of Strongyloides stercoralis
infection. J Infect Dis 2008 Aug 1;198(3):444–51.
[44] Krolewiecki AJ, Ramanathan R, Fink V, McAuliffe I, Cajal SP, Won K,
et al. Improved diagnosis of Strongyloides stercoralis using recombinant
antigen-based serologies in a community-wide study in northern
Argentina. Clin Vaccine Immunol 2010 Oct;17(10):1624–30.
[45] Campo Polanco L, Gutierrez LA, Cardona Arias J. Diagnosis of
Strongyloides stercoralis infection: meta-analysis on evaluation ofClinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf
This is an open access articonventional parasitological methods (1980–2013). Rev Esp Salud
Publica 2014 Oct;88(5):581–600.
[46] Joseph L, Gyorkos TW, Coupal L. Bayesian estimation of disease
prevalence and the parameters of diagnostic tests in the absence of a
gold standard. Am J Epidemiol 1995 Feb 1;141(3):263–72.
[47] Juan Moreira MA, Van de Ende Jef, Gobbo Maria, Endara Jorge,
Degani Monica, Bisofﬁ Zeno. Strongyloidiasis in primary-school chil-
dren of Borbon, Equador—evaluation of prevalence and diagnostic
tests validity by “latent class analysis”. G Ital Med Trop 2006;11(3–4):
51–5.
[48] Reitsma JB, Rutjes AW, Khan KS, Coomarasamy A, Bossuyt PM. A
review of solutions for diagnostic accuracy studies with an imperfect
or missing reference standard. J Clin Epidemiol 2009 Aug;62(8):
797–806.
[49] Boscolo M, Gobbo M, Mantovani W, Degani M, Anselmi M,
Monteiro GB, et al. Evaluation of an indirect immunoﬂuorescence
assay for strongyloidiasis as a tool for diagnosis and follow-up. Clin
Vaccine Immunol 2007 Feb;14(2):129–33.
[50] Sudarshi S, Stumpﬂe R, Armstrong M, Ellman T, Parton S, Krishnan P,
et al. Clinical presentation and diagnostic sensitivity of laboratory tests
for Strongyloides stercoralis in travellers compared with immigrants in a
non-endemic country. Trop Med Int Health 2003 Aug;8(8):728–32.
[51] Angheben A, Mistretta M, Gobbo M, Bonaﬁni S, Iacovazzi T, Sepe A,
et al. Acute strongyloidiasis in Italian tourists returning from Southeast
Asia. J Travel Med 2011 Mar–Apr;18(2):138–40.
[52] Verweij JJ, Canales M, Polman K, Ziem J, Brienen EA, Polderman AM,
et al. Molecular diagnosis of Strongyloides stercoralis in faecal samples
using real-time PCR. Trans R Soc Trop Med Hyg 2009 Apr;103(4):
342–6.
[53] Gordon CA, Gray DJ, Gobert GN, McManus DP. DNA ampliﬁcation
approaches for the diagnosis of key parasitic helminth infections of
humans. Mol Cell Probes 2011 Aug;25(4):143–52.
[54] Moghaddassani H, Mirhendi H, Hosseini M, Rokni M, Mowlavi G, Kia E.
Molecular diagnosis of Strongyloides stercoralis infection by PCR
detection of speciﬁc DNA in human stool samples. Iran J Parasitol
2011 Jun;6(2):23–30.
[55] Mascarello M, Gobbi F, Angheben A, Gobbo M, Gaiera G, Pegoraro M,
et al. Prevalence of Strongyloides stercoralis infection among HIV-posi-
tive immigrants attending two Italian hospitals, from 2000 to 2009. Ann
Trop Med Parasitol 2011 Dec;105(8):617–23.
[56] Ten Hove RJ, Van Esbroeck M, Vervoort T, van den Ende J, van
Lieshout L, Verweij JJ. Molecular diagnostics of intestinal parasites in
returning travellers. Eur J Clin Microbiol Infect Dis 2009 Sep;28(9):
1045–53.
[57] Saugar JM, Merino FJ, Martin-Rabadan P, Fernandez-Soto P, Ortega S,
Garate T, et al. Application of realtime PCR for the detection of
Strongyloides spp. in clinical samples in a reference center in Spain. Acta
Trop 2015;142:20–5.
[58] Datry A, Hilmarsdottir I, Mayorga-Sagastume R, Lyagoubi M,
Gaxotte P, Biligui S, et al. Treatment of Strongyloides stercoralis infection
with ivermectin compared with albendazole: results of an open study
of 60 cases. Trans R Soc Trop Med Hyg 1994 May– Jun;88(3):344–5.
[59] Marti H, Haji HJ, Savioli L, Chwaya HM, Mgeni AF, Ameir JS, et al. A
comparative trial of a single-dose ivermectin versus three days of
albendazole for treatment of Strongyloides stercoralis and other soil-
transmitted helminth infections in children. Am J Trop Med Hyg 1996
Nov;55(5):477–81.
[60] Toma H, Sato Y, Shiroma Y, Kobayashi J, Shimabukuro I, Takara M.
Comparative studies on the efﬁcacy of three anthelminthics on
treatment of human strongyloidiasis in Okinawa, Japan. Southeast
Asian J Trop Med Public Health 2000 Mar;31(1):147–51.
[61] Bisofﬁ Z, Buonfrate D, Angheben A, Boscolo M, Anselmi M,
Marocco S, et al. Randomized clinical trial on ivermectin versus thia-
bendazole for the treatment of strongyloidiasis. PLoS Negl Trop Dis
2011 Jul;5(7):e1254.of European Society of Clinical Microbiology and Infectious Diseases, CMI, 21, 543–552
cle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
552 Clinical Microbiology and Infection, Volume 21 Number 6, June 2015 CMI[62] Ahmad AF, Hadip F, Ngui R, Lim YA, Mahmud R. Serological and
molecular detection of Strongyloides stercoralis infection among an
Orang Asli community in Malaysia. Parasitol Res 2013 Aug;112(8):
2811–6.
[63] Salvador F, Sulleiro E, Sanchez-Montalva A, Saugar JM, Rodriguez E,
Pahissa A, et al. Usefulness of Strongyloides stercoralis serology in the
management of patients with eosinophilia. Am J Trop Med Hyg 2014
May;90(5):830–4.
[64] Biggs BA, Caruana S, Mihrshahi S, Jolley D, Leydon J, Chea L, et al.
Management of chronic strongyloidiasis in immigrants and refugees: Is
serologic testing useful? Am J Trop Med Hyg 2009 May;80(5):788–91.
[65] Pak BJ, Vasquez-Camargo F, Kalinichenko E, Chiodini PL, Nutman TB,
Tanowitz HB, et al. Development of a rapid serological assay for the
diagnosis of strongyloidiasis using a novel diffraction-based biosensor
technology. PLoS Negl Trop Dis 2014 Aug;8(8):e3002.
[66] Notomi T, Okayama H, Masubuchi H, Yonekawa T, Watanabe K,
Amino N, et al. Loop-mediated isothermal ampliﬁcation of DNA.
Nucleic Acids Res 2000 Jun 15;28(12):E63.
[67] Wassermann M, Mackenstedt U, Romig T. A loop-mediated isothermal
ampliﬁcation (LAMP) method for the identiﬁcation of species within
the Echinococcus granulosus complex. Vet Parasitol 2014 Feb
24;200(1–2):97–103.
[68] Ni XW, McManus DP, Lou ZZ, Yang JF, Yan HB, Li L, et al. A com-
parison of loop-mediated isothermal ampliﬁcation (LAMP) with other
surveillance tools for Echinococcus granulosus diagnosis in canine
deﬁnitive hosts. PloS One 2014;9(7):e100877.
[69] Ni X, McManus DP, Yan H, Yang J, Lou Z, Li H, et al. Loop-mediated
isothermal ampliﬁcation (LAMP) assay for the identiﬁcation of Echi-
nococcus multilocularis infections in canine deﬁnitive hosts. Parasites
Vectors 2014;7:254.
[70] Nkouawa A, Sako Y, Nakao M, Nakaya K, Ito A. Loop-mediated
isothermal ampliﬁcation method for differentation and rapid detection
of Taenia species. J Clin Microbiol 2009;47(1):168–74.
[71] Sako Y, Nkouawa A, Yanagida T, Ito A. Loop-mediated isothermal
ampliﬁcation method for a differential identiﬁcation of human Taenia
tapeworms. Methods Mol Biol 2013;1039:109–20.
[72] Davaasuren A, Dorjsuren T, Yanagida T, Sako Y, Nakaya K,
Davaajav A, et al. Recent situation of taeniasis in Mongolia
(2002–2012). Korean J Parasitol 2014 Apr;52(2):211–4.
[73] Drame PM, Fink DL, Kamgno J, Herrick JA, Nutman TB. Loop-medi-
ated isothermal ampliﬁcation for rapid and semiquantitative detection
of Loa loa infection. J Clin Microbiol 2014 Jun;52(6):2071–7.
[74] Fernandez-Soto P, Mvoulouga PO, Akue JP, Aban JL, Santiago BV,
Sanchez MC, et al. Development of a highly sensitive loop-mediated
isothermal ampliﬁcation (LAMP) method for the detection of Loa loa.
PloS One 2014;9(4):e94664.Clinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf of
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/lice[75] Arimatsu Y, Kaewkes S, Laha T, Sripa B. Speciﬁc diagnosis of Opis-
thorchis viverrini using loop-mediated isothermal ampliﬁcation (LAMP)
targeting parasite microsatellites. Acta Trop 2015 Jan;141(Pt B):
368–71.
[76] Chen Y, Wen T, Lai DH, Wen YZ, Wu ZD, Yang TB, et al. Devel-
opment and evaluation of loop-mediated isothermal ampliﬁcation
(LAMP) for rapid detection of Clonorchis sinensis from its ﬁrst inter-
mediate hosts, freshwater snails. Parasitology 2013 Sep;140(11):
1377–83.
[77] Poole CB, Tanner NA, Zhang Y, Evans Jr TC, Carlow CK. Diagnosis of
brugian ﬁlariasis by loop-mediated isothermal ampliﬁcation. PLoS Negl
Trop Dis 2012;6(12):e1948.
[78] Lin Z, Cao J, Zhang H, Zhou Y, Deng M, Li G, et al. Comparison of
three molecular detection methods for detection of Trichinella in
infected pigs. Parasitol Res 2013 May;112(5):2087–93.
[79] Watts MR, James G, Sultana Y, Ginn AN, Outhred AC, Kong F, et al. A
loop-mediated isothermal ampliﬁcation (LAMP) assay for Strongyloides
stercoralis in stool that uses a visual detection method with SYTO-82
ﬂuorescent dye. Am J Trop Med Hyg 2014 Feb;90(2):306–11.
[80] Zhibing L, Yanlei Z, Houshuang Z, Yongzhi Z, Jie C, Jinlin Z. Com-
parison of loop-mediated isothermal ampliﬁcation (LAMP) and real-
time PCR method targeting a 529-bp repeat element for diagnosis of
toxoplasmosis. Vet Parasitol 2011;185(2–4):296–300.
[81] Etheridge A, Lee I, Hood L, Galas D, Wang K. Extracellular microrna: a
new source of biomarkers. Mutat Res 2011 Dec 1;717(1–2):85–90.
PubMed PMID: 21402084.
[82] Kosaka N, Iguchi H, Ochiya T. Circulating microRNA in body ﬂuid: a
new potential biomarker for cancer diagnosis and prognosis. Cancer
Sci 2010 Oct;101(10):2087–92.
[83] Weiland M, Gao XH, Zhou L, Mi QS. Small RNAs have a large impact:
Circulating microRNAs as biomarkers for human diseases. RNA Biol
2012;9(6):850–9.
[84] Anna MH, Rachel JL, Alasdair I, Juan FQ, Norman N, Throsten F, et al.
Parasite-derived microRNAs in host serum as novel biomarkers of
helminth infection. PLoS Negl Trop Dis 2014;8(2).
[85] Lok James B. Strongyloides stercoralis and relatives: recent advances in
general and molecular biology. Curr Trop Med Rep 2014;1(4):
194–206.
[86] Tan JJ, Capozzoli M, Sato M, Watthanaworawit W, Ling CL,
Mauduit M, et al. An integrated lab-on-chip for rapid identiﬁcation and
simultaneous differentiation of tropical pathogens. PLoS Negl Trop Dis
2014 Jul;8(7):e3043.
[87] Basuni M, Muhi J, Othman N, Verweij J, Ahmad M, Miswan N, et al. A
pentaplex real-time polymerase chain reaction assay for detection of
four species of soil-transmitted helminthes. J Trop Med Hyg
2011;84(2):338–43.European Society of Clinical Microbiology and Infectious Diseases, CMI, 21, 543–552
nses/by-nc-nd/4.0/)
